SUMMIT: Tirzepatide Reduces Cardiovascular Events in HFpEF Plus Obesity
In the phase 3 SUMMIT trial, tirzepatide, was found to reduce the risk for worsening heart failure in patients with preserved ejection fraction and obesity. ...
